 stanozolol (anabolic
steroid with proﬁbrinolytic effect) with placebo was performed, but despite previously demonstrated activity on lipodermatosclerosis in CVD, the drug failed to show
superiority over placebo.460 A randomized multicenter
placebo-controlled trial of another proﬁbrinolytic and
antithrombotic drug, sulodexide (puriﬁed glycosaminoglycan), was encouraging and